Ozempic^® (semaglutide injection) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.

Ozempic^® is indicated as an adjunct to diet, exercise, and standard of care to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease. 

Ozempic^® is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

Not a substitute for insulin. Not for use in type 1 diabetes or for the treatment of diabetic ketoacidosis. Ozempic^® is not indicated for use in pediatric patients.

Consult the Ozempic^® Product Monograph at OzempicPM-E.ca or here for important information on:

• Contraindications in personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); hypersensitivity to Ozempic^® or any product components; pregnancy or breastfeeding
• Most serious warnings and precautions about risk of thyroid C-cell tumours
• Other relevant warnings and precautions about intramuscular administration; CV effects/patients with congestive heart failure NYHA Class IV; use in patients with a history of severe gastroparesis/serious GI adverse events; hypoglycemia with concomitant use of insulin secretagogues or insulin; use with other incretin drugs; hepatic insufficiency; pancreatitis; hypersensitivity/patients with history of angioedema or analphylaxis with GLP-1RA; diabetic retinopathy; aspiration in association with general anaesthesia or sedation; renal impairment; driving/operating machinery; dizziness (initial dose escalation); GLP-1 RA class potential for severe GI disease (ileus); acute events of gall bladder disease; acute renal failure or worsening chronic kidney failure associated with GI adverse reactions; non-arteritic anterior ischemic optic neuropathy (NAION)
• Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

The Product Monograph is also available by calling us at 1-800-465-4334.